Biogen is a global biotechnology company committed to bringing high-quality medical treatments to market. For nonprofits focused on multiple sclerosis, Alzheimer's and Parkinson's, Biogen's pioneering efforts to integrate quantum computing alter the landscape of high impact grantmaking. Today's education grants will play an important role in building a talent pool prepared to work with these emerging technologies.
Try the Quantum Card Test to experience the difference between traditional computing power and qubits.
Learn more: "Biotechnology company Biogen Inc. has completed an experiment that shows that quantum computers have the potential to speed up drug discovery for diseases such as multiple sclerosis, Alzheimer’s and Parkinson’s. The Cambridge, Mass.-based firm, which declined to be interviewed for this story, is the latest company to experiment with cutting-edge technology that harnesses the power of quantum mechanics to solve complex problems in nanoseconds. Experts say that within five years quantum computing will be powerful enough to solve problems that are currently beyond the scope of today’s most advanced computers." (Castellanos, 6/13/17)
"Protein folding and drug discovery: Simulated annealing is an algorithm currently used for the prediction of the effects of potential therapeutic approaches while optimizing for non-adverse effects. Quantum computing can replace some of these techniques, and may be able to show improvements at scale in the next few years such as advancing drug design to the point of providing personalized prescription drugs for individual patients." Read More